The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients

Cognitive Impairment Clinical Trial

Official title:

The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05872646
• Other study ID #: PamukkaleU-simsek-parkinson-01
• Status: Completed
• Phase: N/A
• Start date: February 8, 2018
• Est. completion date: March 10, 2023

Study information

• Verified date: May 2023
• Source: Pamukkale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.

Description:

Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. Involvement of nigrostriatal dopaminergic neurons is associated with the motor manifestations of the disease. The most common of these symptoms are; resting tremor, bradykinesia, rigidity and balance disorder. However, non-motor symptoms related to the involvement of nervous system structures other than the dopaminergic nigrostriatal system can be observed in PD. However, due to the predominance of motor symptoms in PD, it took many years to notice cognitive changes. Traditionally, cognitive impairments in PD have been expected to occur in the advanced stages of the disease. However, cognitive impairments in the early stages are reported in approximately 30-35% of patients. Cognitive dysfunction is defined in PD, ranging from mild impairments in certain cognitive domains to severe dementia. Cognitive impairment primarily affects executive and visuospatial functions, and memory is secondarily affected. Executive functions are higher cognitive processes that use and modify information from many cortical sensory systems in the fore and hindbrain areas to modulate and teach behavior. The frontal cortex, especially the prefrontal cortex and its striatal connections are very important neuroanatomical regions for executive functions. The relationship between the effects of cognition and motor performance and parameters in groups such as the elderly, PD and Alzheimer's patients in which these centers are affected has been an issue that has attracted the attention of many researchers. Most of the studies have focused on the lower extremity performance of cognition. However , it has been reported that cognition has positive effects on upper extremity performance and early acquired upper extremity skills have positive effects on cognitive performance . The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 104
• Est. completion date: March 10, 2023
• Est. primary completion date: March 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

• Having a diagnosis of Parkinson's Disease.
• Not having hearing and vision problems.
• To be able to take the commands required for the manual dexterity tests.
• Agree to participate in the study.

Exclusion Criteria:

• Having undergone musculoskeletal surgery for the upper extremity.
• Having vision and hearing problems.
• Having an additional disease that may affect cognitive tests.

Related Conditions & MeSH terms

• Cognitive Impairment
• Functional Disturbance
• Parkinson
• Parkinson Disease
• Upper Extremity Problem

Intervention

Diagnostic Test:
• clinical assessment
clinical staging

Locations

Country	Name	City	State
Turkey	Pamukkale University	Denizli

Sponsors (1)

Lead Sponsor	Collaborator
Pamukkale University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Modified Hoehn Yahr Scale	Used for clinical staging of Parkinson's disease	1 year
Primary	Unified Parkinson's Disease Rating Scale	Used for the evaluation of clinical manifestations of Parkinson's disease	1 year
Primary	Parkinson's Disease Questionnaire-PDQ 39	Used to assess the quality of life of Parkinson's patients	1 year
Secondary	Stroop Test	measures the selective attention ability of individuals	1 year
Secondary	Wechsler Memory Scale-Revised	To assess attention, learning, memory and working memory in individuals aged 16-89	1 year
Secondary	Dexterity Questionnaire-24	To assess manuel dexterity	1 year
Secondary	Nine Hole Peg Test	To assess manuel dexterity	1 year